New drug combo aims to slow advanced cervical cancer
NCT ID NCT05521997
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding a glutaminase inhibitor (telaglenastat) to standard chemoradiation helps people with advanced cervical cancer live longer without the disease getting worse. About 42 adults with stage III–IVA cervical cancer will receive the drug alongside standard treatment. The goal is to see if this combination delays cancer progression compared to historical results with standard care alone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED CERVICAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Can an antiviral make radiation more effective against cervical cancer?
- A One-Two punch against cervical cancer: testing plus vaccination in HIV-Positive women
- Can a Two-Antibody combo outsmart advanced cancer?
- Can robotic surgery match open surgery in beating cervical cancer?
- Blood test clues could sharpen cervical cancer treatment